China’s Emerging Global Vaccine Footprint
While demand for COVID-19 vaccines may be decreasing, the pandemic highlighted the long-term importance of boosting local vaccine manufacturing in developing countries. China’s role as a key vaccine donor and provider during the pandemic has positioned it to support this new agenda, making it a critical emerging player in the global vaccine manufacturing landscape. As a mission-driven consultancy looking to encourage China’s engagement in global health, Bridge Consulting aims to identify and drive China’s involvement in this important endeavor.
Article Series: Towards Africa's Local Vaccine Manufacturing
Latest News
Pandemic Preparedness
BRICS member states, Africa CDC and WHO commit to collaborate with Business sector on Pandemic Prevention, Preparedness and Response — Africa CDC
As UN Pandemic Talks Resume, Tedros Expresses ‘Concern’ About Slow Pace of Accord Negotiations — Health Policy Watch
From private incentives to public health need: rethinking research and development for pandemic preparedness — The Lancet
Joint Vaccine Production
CanSino signs mRNA vaccine manufacturing deal with AstraZeneca, providing CDMO services for up to 10 years — CanSino
Walvax signed agreement with VBC Biotechnology City for cooperation in the distribution and localized production of Walvax’s 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, PCV-13, in Egypt and its neighboring countries. — Walvax
Local Manufacturing
Africa CDC Donates Equipment to SAHPRA to Support Regulatory Functions in Vaccine Manufacturing — Africa CDC
MoreGallery of Visualizations
